… ProQR Receives Orphan Drug Designation from FDA for QR-1123 … Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … or adRP,” said Daniel de Boer, Chief Executive Officer of ProQR. “It highlights the unmet need for patients with this …
… ProQR to Participate in a Cystic Fibrosis Panel Discussion … LEIDEN, The Netherlands, June 13, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that … being held at The St. Regis in New York, NY, USA. About ProQRProQR Therapeutics is dedicated to changing lives …
… ProQR Receives Fast Track Designation from FDA for QR-1123 … Mass., Sept. 09, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … disease,” said Daniel de Boer, Chief Executive Officer of ProQR. “We look forward to beginning enrollment in the Phase …
… ProQR spins out Amylon Therapeutics as a privately-held … on central nervous system (CNS) therapeutics Key updates ProQR spins out CNS-focused company, Amylon Therapeutics, … and private investors. As part of the transaction, ProQR has granted an exclusive license to Amylon to develop …
… ProQR Prices Approximately $20 Million Underwritten Public … LEIDEN, The Netherlands, Nov. 14, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical … $3.25 per share. All of the shares are being offered by ProQR. In addition, in the public offering, ProQR has …
… ProQR Announces Last Patient Has Completed 12 Month Visit in … & CAMBRIDGE, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … Daniel A. de Boer, Founder and Chief Executive Officer of ProQR. “Based on this event, we now anticipate sharing the …
… ProQR Receives Orphan Drug Designation from EMA for Drug … QR-313 for Dystrophic Epidermolysis Bullosa Key Updates ProQR’s drug candidate, QR-313 for dystrophic epidermolysis …